A part of Watch Media

MedWatchWednesday1 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
22/06/2021at 14:06

Financial analyst: Novo Nordisk's obesity treatment could triple market

Jefferies' analysts have consulted with an expert on obesity and diabetes treatments, and now, the investment banking company sees a real possibility that the market for obesity treatment will grow significantly.
Photo: Novo Nordisk / PR
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

Novo Nordisk's novel weight loss drug Wegovy has the potential to at least double or triple the market, writes investment banking company Jefferies in a report.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Tidsvilde Stine/Ritzau Scanpix

    Novo Nordisk expands collaboration with US app company

    For subscribers

  • Photo: Coloplast / PR

    Coloplast sees potential in Russia

    For subscribers

  • Novo Nordisk President & CEO | Photo: Stine Bidstrup/ERH

    Novo Nordisk CEO's pay sets itself apart on especially one point

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Viatris's headquaters in Pittsburgh, Pennsylvania, US | Foto: Viatris/PR.
Pharma & biotech

Novo Nordisk sues Viatris over copycat Wegovy

A market authorization application from US-based generics maker Viatris for a copy version of obesity treatment Wegovy breaches five of Novo Nordisk’s patents, claims the company in a lawsuit.
  • Novo Nordisk doubles obesity sales in 2022
  • New US lawsuit over insulin prices will have minimal impact on Novo Nordisk, says analyst

For subscribers

Foto: Arnd Wiegmann/Reuters/Ritzau Scanpix
Pharma & biotech

Novartis beats Kesimpta sales expectations in Q4

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix
Pharma & biotech

Analyst: Strong Novo Nordisk outlook should satisfy investors

For subscribers

Foto: Jens Dresling/Ritzau Scanpix
Pharma & biotech

Studies of Wegovy in higher-than-approved doses begin

For subscribers

Foto: Novo Nordisk
Pharma & biotech

Rare Disease business comes in slightly below expectations for Novo Nordisk

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk meets upgraded guidance, setting new revenue record

For subscribers

Further reading

Anders Hinsby (left), Thomas Kirkegaard Jensen, and Anders Vadsholt | Photo: Anne Bæk/Ritzau Scanpix
Pharma & biotech

Orphazyme trio founds new firm focused on neurology and rare diseases

Anders Hinsby, Anders Vadsholt, and Thomas Kirkegaard Jensen – all three key figures from now-defunct biotech company Orphazyme – have established a new company using experiences from the past.

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk predicts wide range for 2023 sales growth

The Danish drugmaker has released its 2023 guidance with a sales growth expectation of 13–19%. (Updated)

For subscribers

Foto: Novo Nordisk / PR
Pharma & biotech

Novo Nordisk wins case in US appeals court

Three pharmaceutical firms, including Novo Nordisk, have won a case in a US appeals court, which agreed that the drugmakers can limit deliveries of federally discounted drugs.

For subscribers

Latest news

  • Potential blockbuster submitted by Novo Nordisk for European approval – 13:51
  • Novo Nordisk sues Viatris over copycat Wegovy – 12:46
  • Novartis beats Kesimpta sales expectations in Q4 – 11:49
  • Analyst: Strong Novo Nordisk outlook should satisfy investors – 11:09
  • Studies of Wegovy in higher-than-approved doses begin – 10:01
  • Rare Disease business comes in slightly below expectations for Novo Nordisk – 09:48
  • Novo Nordisk meets upgraded guidance, setting new revenue record – 09:20
  • Novo Nordisk doubles obesity sales in 2022 – 08:54
  • Maersk and German start-up wants to enhance emission visibility for global e-trade – 08:27
  • Novo Nordisk predicts wide range for 2023 sales growth – 07:38
See all

Jobs

  • Regulatory Affairs Professional

  • Application Manager

  • Clinical Operational Associate

  • Commercial Director

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Experienced Patent Counsel

  • Lead Data Architect

  • Sr. Director, Drug Safety Physician

  • Senior Regulatory Affairs Professional

  • Head of Regulatory Affairs Danmark

  • Application Manager

See all jobs

Jobs

  • Regulatory Affairs Professional

  • Application Manager

  • Clinical Operational Associate

  • Commercial Director

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Experienced Patent Counsel

  • Lead Data Architect

  • Sr. Director, Drug Safety Physician

  • Senior Regulatory Affairs Professional

  • Head of Regulatory Affairs Danmark

  • Application Manager

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge